03.11.25 -- Which Of These 6 Outsourcing Models Best Suits Your Program?

As rare disease research continues to evolve, particularly with breakthroughs in precision medicine, the partnership between patient communities and biotech companies has never been more important.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

The biopharmaceutical industry faces a multitude of challenges. Learn how a collaborative outsourcing partnership based on trust and transparency can foster efficient and high-quality drug production.

Review four key factors for improving on-time delivery when outsourcing drug product manufacturing and discover how investing in building a solid relationship with your CDMO improves timelines.

Radiofrequency identification (RFID)-based unit-level tracking solutions for prefilled syringes are poised to help pharma manufacturers address key risks and costly bottlenecks related to the fill-finish process.

Antibody-drug conjugates' manufacturing supply chain contains five different technologies with specific asset needs: monoclonal antibody, cytotoxic payload, linker, bioconjugation, and fill & finish.